New York, United States
Everest Medicines, founded in 2017, is a biotechnology firm headquartered in the United States with a focus on developing novel pharmaceuticals for mainland China and broader Asian markets. Operating under the slogan "Better Medicines, Better Life", the company aims to bridge critical unmet medical needs by collaborating with innovative global entities.
The company's expertise spans clinical development, regulatory affairs, and business operations, leveraging partnerships with major pharmaceutical companies. Despite its young age, Everest Medicines has rapidly established itself as a key player in the Biotechnology, Health Care, and Pharmaceutical industries.
The startup secured a substantial $310 million in a Series C round on 03 June 2020, with investments from notable firms like HBM Healthcare Investments, RA Capital Management, and CBC Group, among others. Their initial Series A was led by C-Bridge Capital, evidencing robust backing from premier private equity channels.
-Limited-logo.jpg "BioNova Pharmaceuticals (Shanghai) Limited"){kind=logo}
